Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

GenScript ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology

NANJING, China, Feb. 18, 2021 /PRNewswire/ -- On February 7th, 2021, GenScript ProBio announced that it has successfully completed 3 X 200 L GMP production runs of recombinant human factor VIII (rhFVIII) for Beijing Neoletix Biological Technology Co., Ltd. (Neoletix). InMay 2019, GenScript ProBio...

2021-02-18 22:00 2259

United Imaging Announces Agreement with Vizient for Computed Tomography Systems.

HOUSTON, Feb. 18, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced an agreement to offer its suite of cutting-edge Computed Tomography technology to Vizient members at contracted pricing. For maximum clinical flexibility, all ...

2021-02-18 21:00 2069

Everest Medicines Appoints Kevin Guo as Chief Commercial Officer

SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater C...

2021-02-18 12:21 3956

Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD

ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF,Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary ofGermany-based CNS clinical development...

2021-02-17 19:00 6533

Bionic Vision Technologies Advances Clinical Program With AU$1 million Medical Research Future Fund Grant

MELBOURNE, Australia, Feb. 16, 2021 /PRNewswire/ -- Bionic Vision Technologies (BVT) has started work on the next phase of development for its world-leading Australian bionic eye technology thanks to a recent Australian Government grant to refine its vision processing algorithms. BVT's bionic ey...

2021-02-17 08:03 1756

Breg and Club Warehouse Launch Partnership in Australia

Breg Expands Orthopedic Product Offering to Providers and Sports Organizations acrossAustralia including AFL, NRL and Rugby Union Clubs CARLSBAD, California, Feb. 16, 2021 /PRNewswire/ -- Breg, Inc., a leading orthopedic bracing and billing services company, announced today that it has partnered...

2021-02-16 02:29 2130

VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock

AUSTIN, Texas, Feb. 12, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers ...

2021-02-12 22:25 12031

China SXT Pharmaceuticals, Inc. Enters into Non-Binding LOI to Acquire Jiangsu Renji Pharmaceutical Chain Co., Ltd.

TAIZHOU, China, Feb. 11, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company") announced today that it has entered into a non-binding letter of intent with Jiangsu Renji Pharmaceutical Chain Co., Ltd. ("Renji Chain"). Pursuant to the terms of the LOI,...

2021-02-11 21:00 4227

GenScript Receives FDA Emergency Use Authorization for Use of cPass(TM) SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening

PISCATAWAY, N.J., Feb. 11, 2021 /PRNewswire/ -- GenScript USA Inc ., the world's leading life science research tools and services provider, announced today that it has received Emergency Use Authorization by the U.S. Food and ...

2021-02-11 20:30 1798

Transcenta Holding Announces Appointment of Dr. Michael Shi as Executive Vice President, Head of Global R&D and Chief Medical Officer

SUZHOU, China, Feb. 10, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the appointment of Dr.Michael Shi as Executive Vic...

2021-02-11 08:00 1960

I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Feb. 10, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China N...

2021-02-10 21:00 5608

Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial

BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the successful completion of dosing of the first pati...

2021-02-10 19:12 2155

$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial

* Commitments received for a placement of A$15,991,634 at A$0.145 per share * Significant participation from North American and European institutional and sophisticated investors * This capital raising enables proceeding with the Phase 2b PTSD trial in mid-2021 as planned and sees the Compan...

2021-02-10 19:00 8657

Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials

NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's di...

2021-02-09 21:53 3806

Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced

SHANGHAI and GAITHERSBURG, Md., Feb. 9, 2021 /PRNewswire/ -- A registered follow-on public offering by certain pre-IPO shareholders (the "Selling Shareholders") of 3,283,950 American depositary shares (the "ADSs" and such offering, the "ADS Offering") of I-Mab (the "Company") (Nasdaq: IMAB), a c...

2021-02-09 21:00 9747

Chinese Aesthetic Treatment Industry White Paper 2020 Jointly Released By AIH and Forbes China

SHENZHEN, China, Feb. 9, 2021 /PRNewswire/ -- Aesthetic Medical International Holdings Group Limited (the "Company" or "AIH", Nasdaq: AIH), a leading provider of aesthetic medical services inChina, and Forbes China have jointly releasedthe Chinese Aesthetic Treatment Industry White Paper 2020 (t...

2021-02-09 18:00 2951

Experiment showed that Jemincare's neutralizing antibody JMB2002 would likely keep the potency against the South African mutant

SHANGHAI, Feb. 8, 2021 /PRNewswire/ -- On February 7, 2021, scientists from Jemincare Shanghai Research Institute published a preprint paper on BioRxiv, the paper entitled "A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prop...

2021-02-09 11:18 2008

Experiment showed that Jemincare's neutralizing antibody JMB2002 would likely keep the potency against the South African mutant

Cooperation Agreement with Terumo Blood And Cell Technologies to Promote and Sell Osteopore Products

Highlights: * Cooperation Agreement with Terumo Blood and Cell Technologies to promote and sell both companies complementary regenerative products inAsia-Pacific. * Terumo Blood and Cell Technologies' products will be used to concentrate a patient's bone marrow and mixed into Osteopore scaffo...

2021-02-08 21:21 2274

Longevity Acquisition Corporation Announces 4D pharma Clinical Trial Collaboration and Supply Agreement for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 8, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...

2021-02-08 21:00 7828

Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab

SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the commencement of a proposed registered underwritten pu...

2021-02-06 06:27 9656

1 ... 245 246 247248249 250